Madrigal's Cholesterol Drug Succeeds in Mid-Stage Trial Post author:Sam Post published:February 7, 2018 Post category:BioPharma MGL-3196 was well-tolerated with primarily mild and some moderate AEs. Source: BioSpace You Might Also Like Why Novavax Could be a Millionaire-Maker Stock February 15, 2018 2 Biotechs That May Disappear by 2020 March 30, 2017 Meet This Largely Over-Looked Phase 3 Alzheimer's Company January 30, 2017
